BRAF and acute myeloblastic leukemia with maturation: Interestingly, BRAF inhibitors offer promising results in the treatment of BRAF-positive AM, indicating the feasibility of treating AM by targeting tumor driver genes.7–10 These findings emphasize the need for a better understanding of mechanisms governing the progression of AM, which may provide effective therapeutic strategies for the eradication of AM.